.Pharmacolibrary.Drugs.C_CardiovascularSystem.C01E_OtherCardiacPreparations.C01EB17_Ivabradine.Ivabradine

Information

Ivabradine is a selective inhibitor of the cardiac pacemaker If current, reducing heart rate without affecting myocardial contractility or intracardiac conduction. It is used for the symptomatic treatment of chronic stable angina pectoris and chronic heart failure. Ivabradine is approved in many countries for these indications.

Pharmacokinetics

Pharmacokinetic parameters in healthy adult subjects after oral administration of ivabradine 10 mg single dose.

References

1. Peigné, S, et al., & Chenel, M (2016). Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessment. Journal of pharmacokinetics and pharmacodynamics 43(1) 13–27. DOI:10.1007/s10928-015-9451-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/26563503

2. Peigné, S, et al., & Chenel, M (2016). Model-based approaches for ivabradine development in paediatric population, part II: PK and PK/PD assessment. Journal of pharmacokinetics and pharmacodynamics 43(1) 29–43. DOI:10.1007/s10928-015-9452-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/26578442

3. Choi, HY, et al., & Lim, HS (2013). Evaluation of pharmacokinetic and pharmacodynamic profiles and tolerability after single (2.5, 5, or 10 mg) and repeated (2.5, 5, or 10 mg bid for 4.5 days) oral administration of ivabradine in healthy male Korean volunteers. Clinical therapeutics 35(6) 819–835. DOI:10.1016/j.clinthera.2013.04.012 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23755867

Revisions

• 06/2025 initial generated model